GlaxoSmithKline links with Japan's Chiome on MAbs

10 April 2012

UK pharma giant GlaxoSmithKline group (LSE: GSK) and Tokyo, Japan-based biotech-venture company Chiome Bioscience (TYO:4583) have entered into a pilot study and option agreement under which the two companies will generate monoclonal antibodies (MAbs) using Chiome's proprietary ADLib system for GSK’s research and evaluation use with an option for development. Financial terms of the accord were not disclosed.

The combination of GSK’s world’s top class research and development activities in drug development with Chiome’s innovative platform technology for antibody generation has the potential to accelerate drug discovery and advance pharmaceutical development which offers new treatment options to patients suffering from cancer and autoimmune diseases, said the Japanese firm.

About the ADLib system

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK